The following are the top rated Healthcare stocks according to Validea's Small-Cap Growth Investor model based on the published strategy of Motley Fool. This strategy looks for small cap growth stocks with solid fundamentals and strong price performance.
ZYNEX INC. (ZYXI) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Motley Fool is 83% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Zynex, Inc. operates through the Electrotherapy and Pain Management Products segment. The Company conducts its business through its subsidiaries and the operating subsidiary is Zynex Medical, Inc. (ZMI). Its other subsidiaries include Zynex Monitoring Solutions, Inc. (ZMS) and Zynex Europe, ApS (ZEU). ZMI designs, manufactures and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. ZMS is in the process of developing its blood volume monitoring product for non-invasive cardiac monitoring. ZEU intends to focus on sales and marketing its products within the international marketplace, upon receipt of necessary regulatory approvals. It markets and sells Zynex-manufactured products and distributes private labeled products. Its products include NexWave, NeuroMove, InWave, Electrodes and Batteries. ZMI devices are intended for pain management to reduce reliance on drugs and medications.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
| PROFIT MARGIN: | PASS |
| RELATIVE STRENGTH: | PASS |
| COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: | FAIL |
| INSIDER HOLDINGS: | PASS |
| CASH FLOW FROM OPERATIONS: | PASS |
| PROFIT MARGIN CONSISTENCY: | PASS |
| R&D AS A PERCENTAGE OF SALES: | NEUTRAL |
| CASH AND CASH EQUIVALENTS: | PASS |
| INVENTORY TO SALES: | PASS |
| ACCOUNTS RECEIVABLE TO SALES: | PASS |
| LONG TERM DEBT/EQUITY RATIO: | PASS |
| "THE FOOL RATIO" (P/E TO GROWTH): | FAIL |
| AVERAGE SHARES OUTSTANDING: | PASS |
| SALES: | PASS |
| DAILY DOLLAR VOLUME: | PASS |
| PRICE: | PASS |
| INCOME TAX PERCENTAGE: | FAIL |
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
LEMAITRE VASCULAR INC (LMAT) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Motley Fool is 80% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: LeMaitre Vascular, Inc. is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment. The Company's product lines include valvulotomes, balloon catheters, carotid shunts, biologic vascular patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, prosthetic vascular grafts, biologic vascular grafts and powered phlebectomy devices. Its portfolio of peripheral vascular devices consists of brand name products that are used in arteries and veins outside of the heart, including the Expandable LeMaitre Valvulotome, the Pruitt F3 Carotid Shunt, VascuTape Radiopaque Tape and the XenoSure biologic patch.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
| PROFIT MARGIN: | PASS |
| RELATIVE STRENGTH: | FAIL |
| COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: | FAIL |
| INSIDER HOLDINGS: | PASS |
| CASH FLOW FROM OPERATIONS: | PASS |
| PROFIT MARGIN CONSISTENCY: | PASS |
| R&D AS A PERCENTAGE OF SALES: | NEUTRAL |
| CASH AND CASH EQUIVALENTS: | PASS |
| INVENTORY TO SALES: | PASS |
| ACCOUNTS RECEIVABLE TO SALES: | PASS |
| LONG TERM DEBT/EQUITY RATIO: | PASS |
| "THE FOOL RATIO" (P/E TO GROWTH): | FAIL |
| AVERAGE SHARES OUTSTANDING: | PASS |
| SALES: | PASS |
| DAILY DOLLAR VOLUME: | PASS |
| PRICE: | PASS |
| INCOME TAX PERCENTAGE: | PASS |
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
INMODE LTD (INMD) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Motley Fool is 79% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Inmode Ltd is an Israel-based company. It designs, develops, manufactures and commercializes energy-based, minimally-invasive surgical aesthetic and medical treatment solutions. The Company's proprietary technologies are used by physicians to remodel subdermal adipose, or fatty, tissue in a variety of procedures including fat reduction with simultaneous skin tightening, face and body contouring and ablative skin rejuvenation treatments. Its products target a wide array of procedures including simultaneous fat killing and skin tightening, permanent hair reduction, skin appearance and texture, among others. The Company's products may be used on a variety of body parts, including the face, neck, abdomen, upper arms, thighs and intimate feminine regions. It owns six product platforms: BodyTite, Optimas, Votiva, Contoura, Triton and EmbraceRF. All are market and sell traditionally to plastic and facial surgeons, aesthetic surgeons and dermatologists, among others.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
| PROFIT MARGIN: | PASS |
| RELATIVE STRENGTH: | PASS |
| COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: | PASS |
| INSIDER HOLDINGS: | FAIL |
| CASH FLOW FROM OPERATIONS: | PASS |
| PROFIT MARGIN CONSISTENCY: | PASS |
| R&D AS A PERCENTAGE OF SALES: | NEUTRAL |
| CASH AND CASH EQUIVALENTS: | PASS |
| INVENTORY TO SALES: | PASS |
| ACCOUNTS RECEIVABLE TO SALES: | PASS |
| LONG TERM DEBT/EQUITY RATIO: | PASS |
| "THE FOOL RATIO" (P/E TO GROWTH): | FAIL |
| AVERAGE SHARES OUTSTANDING: | PASS |
| SALES: | PASS |
| DAILY DOLLAR VOLUME: | FAIL |
| PRICE: | PASS |
| INCOME TAX PERCENTAGE: | FAIL |
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
BIOLIFE SOLUTIONS INC (BLFS) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Motley Fool is 76% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: BioLife Solutions, Inc. (BioLife) is engaged in the developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management application for shippers. The Company's product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs; generic blood stem cell freezing and cell thawing media products; custom product formulation and custom packaging services; cold chain logistics services incorporating precision thermal packaging products and cloud-hosted Web applications, and contract aseptic manufacturing formulation, fill and finish services of liquid media products. Its products include HypoThermosol FRS, CryoStor, BloodStor, Cell Thawing Media, PrepaStor and biologistex cold-chain management service.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
| PROFIT MARGIN: | PASS |
| RELATIVE STRENGTH: | FAIL |
| COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: | FAIL |
| INSIDER HOLDINGS: | PASS |
| CASH FLOW FROM OPERATIONS: | PASS |
| PROFIT MARGIN CONSISTENCY: | PASS |
| R&D AS A PERCENTAGE OF SALES: | NEUTRAL |
| CASH AND CASH EQUIVALENTS: | PASS |
| INVENTORY TO SALES: | PASS |
| ACCOUNTS RECEIVABLE TO SALES: | PASS |
| LONG TERM DEBT/EQUITY RATIO: | PASS |
| "THE FOOL RATIO" (P/E TO GROWTH): | FAIL |
| AVERAGE SHARES OUTSTANDING: | PASS |
| SALES: | PASS |
| DAILY DOLLAR VOLUME: | PASS |
| PRICE: | PASS |
| INCOME TAX PERCENTAGE: | FAIL |
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
MEDPACE HOLDINGS INC (MEDP) is a mid-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Motley Fool is 76% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Medpace Holdings, Inc. is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company's drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company's operations are principally based in North America, Europe, and Asia.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
| PROFIT MARGIN: | PASS |
| RELATIVE STRENGTH: | FAIL |
| COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: | FAIL |
| INSIDER HOLDINGS: | PASS |
| CASH FLOW FROM OPERATIONS: | PASS |
| PROFIT MARGIN CONSISTENCY: | PASS |
| R&D AS A PERCENTAGE OF SALES: | PASS |
| CASH AND CASH EQUIVALENTS: | FAIL |
| ACCOUNTS RECEIVABLE TO SALES: | PASS |
| LONG TERM DEBT/EQUITY RATIO: | PASS |
| "THE FOOL RATIO" (P/E TO GROWTH): | PASS |
| AVERAGE SHARES OUTSTANDING: | PASS |
| SALES: | FAIL |
| DAILY DOLLAR VOLUME: | PASS |
| PRICE: | PASS |
| INCOME TAX PERCENTAGE: | PASS |
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
Since its inception, Validea's strategy based on Motley Fool has returned 639.27% vs. 234.94% for the S&P 500. For more details on this strategy, click here
About Motley Fool: Brothers David and Tom Gardner often wear funny hats in public appearances, but they're hardly fools -- at least not the kind whose advice you should readily dismiss. The Gardners are the founders of the popular Motley Fool web site, which offers frank and often irreverent commentary on investing, the stock market, and personal finance. The Gardners' "Fool" really is a multi-media endeavor, offering not only its web content but also several books written by the brothers, a weekly syndicated newspaper column, and subscription newsletter services.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
